Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBIT: 2014-2024

Historic EBIT for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$536.0 million.

  • Ultragenyx Pharmaceutical's EBIT fell 29.47% to -$170.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$544.0 million, marking a year-over-year decrease of 1.54%. This contributed to the annual value of -$536.0 million for FY2024, which is 5.84% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its EBIT stood at -$536.0 million for FY2024, which was up 5.84% from -$569.2 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's EBIT's 5-year high stood at -$330.1 million during FY2020, with a 5-year trough of -$648.9 million in FY2022.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median EBIT value was -$569.2 million (recorded in 2023), while the average stood at -$584.7 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's EBIT rose by 22.17% in 2020 and then crashed by 69.99% in 2022.
  • Ultragenyx Pharmaceutical's EBIT (Yearly) stood at -$330.1 million in 2020, then dropped by 15.64% to -$381.7 million in 2021, then crashed by 69.99% to -$648.9 million in 2022, then rose by 12.28% to -$569.2 million in 2023, then rose by 5.84% to -$536.0 million in 2024.